BRÈVE

sur Evotec AG (NASDAQ:EVTCY)

Evotec and Bristol Myers Squibb Expand Protein Degradation Partnership

Evotec SE and Bristol Myers Squibb have announced the advancement of their strategic protein degradation collaboration with a second Investigational New Drug (IND) acceptance from the FDA. This clearance broadens their molecular glue pipeline. Launched in 2018, the partnership utilizes Evotec’s cutting-edge multi-omics screening and AI-assisted analytics alongside Bristol Myers Squibb’s CELMoD agent library to develop groundbreaking molecular glue degraders targeting difficult oncological proteins.

The second drug candidate, a cereblon E3 ligase modulator, is set to begin Phase 1 clinical trials in 2027. This development marks a continuation of their success in translating complex biology into therapeutic solutions aimed at addressing substantial unmet medical needs. The advanced platforms used in this partnership ensure the identification and development of promising drug candidates, reinforcing their role in innovative cancer treatment research.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Evotec AG